Researchers identify novel target for high-risk multiple myeloma
High-risk multiple myeloma is an aggressive disease in which plasma cells grow ?uncontrollably. It is typically resistant to treatment and the prognosis for patients is poor. However, the genes that contribute to this behavior are not fully understood. Using single-cell transcriptomics, researchers led by Robert Orlowski, M.D., Ph.D., identified that CLPP, a protein in mitochondria, is overexpressed in high-risk cases and may also...
Targeting cells that form blood vessels in glioblastoma could improve treatment
The formation of new, small blood vessels ¨C known as microvascular proliferation (MVP) ¨C is a hallmark of glioblastoma, the most common and...
Researchers identify CREM as a critical regulator of CAR NK cell function
Chimeric antigen receptor (CAR) natural killer (NK) cells represent a promising experimental cell therapy, but the molecular mechanism regulating...
Study uncovers novel role for BRCA2, suggesting new therapeutic strategies
BRCA2, a key tumor suppressor that helps repair and protect DNA during replication, is often mutated in cancer cells. Normally, BRCA2 interacts with another protein, RAD51, to suppress genomic instability by fixing damage at DNA breaks or by protecting DNA at stalled replication forks, which can occur during DNA replication. ?By examining the protein structure of a specific region of BRCA2, known as the C-terminal end, researchers...
